# Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes

Study · id `cardio:ct-nct03226210` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03226210](<https://clinicaltrials.gov/study/NCT03226210>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03226210

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT03226210. Randomized; single masking; primary purpose treatment. Start 2015-02-01 (actual); primary completion 2016-05-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT03226210, source copy `cardio:ctgov-nct03226210-2017-07-21`, retrieved 2026-10-26)
- Started: 2015-02-01 (actual) (ClinicalTrials.gov record NCT03226210, source copy `cardio:ctgov-nct03226210-2017-07-21`, retrieved 2026-10-26)
- Primary completion: 2016-05-01 (actual) (ClinicalTrials.gov record NCT03226210, source copy `cardio:ctgov-nct03226210-2017-07-21`, retrieved 2026-10-26)
- Completion: 2016-07-01 (actual) (ClinicalTrials.gov record NCT03226210, source copy `cardio:ctgov-nct03226210-2017-07-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03226210, source copy `cardio:ctgov-nct03226210-2017-07-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03226210-2017-07-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): aspart insulin or lipro insulin
- Lead sponsor: Nanjing First Hospital, Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Nanjing First Hospital, Nanjing Medical University (`cardio:org-nanjing-first-hospital-nanjing-medical-university`)

## Provenance

Content hash: eea665f5e5e5d58e78c9c674e19abcd4dbee70ca42d3c2471ea91499484ef4b2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
